Research programme: 11-beta hydroxysteroid dehydrogenase inhibitors - Exelixis
Alternative Names: XL 903Latest Information Update: 10 Mar 2011
At a glance
- Originator Exelixis
- Class
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 22 Feb 2011 Discontinued - Preclinical for Metabolic disorders in USA (PO)
- 05 Dec 2007 Preclinical trials in Metabolic disorders in USA (PO)
- 14 Apr 2005 No development reported - Preclinical for Metabolic disorders in USA (unspecified route)